By playing, you agree to uListen's Terms and Privacy Policy and YouTube's Terms of Service.
Peter Attia MD416 ‒ The science of mitochondria: their role in health, aging, disease, and much more
Summaries, chapters, transcripts, and FAQs on this page are made by uListen, not YouTube.
Great conversations run long. Their best ideas don't have to.
uListen is free on iPhone, iPad, Android, Chrome, and Claude.
See howTranscript
130 min read · 25,593 words- 0:00 – 0:11
Intro
- PAPeter Attia
[upbeat music] Hey everyone, welcome to the Drive podcast. I'm your host, Peter Attia. [upbeat music]
- 0:11 – 7:09
Mitochondrial function: energy production, cellular building blocks, and signaling beyond the powerhouse model
- PAPeter Attia
Nav, good to see you again, my friend.
- NCNav Chandel
Great to see you. Thanks for the invite.
- PAPeter Attia
Thank you for coming down. I suspect that a number of people listening to us today may have not heard us speak eight, six, seven years ago.
- NCNav Chandel
[laughs]
- PAPeter Attia
I don't remember. Um, and if they did, I'm sure it's easy to forget, and there's so much new stuff to talk about. But I always like to kind of ground people in, um, what the mitochondria are. Unfortunately, mitochondria has become one of the top 10 buzzwords on social media, so, um, there's no chance that anybody listening or watching us, um, hasn't heard the term. Um, but that second and third order understanding might be a little foggy, and given that we're gonna talk so much about mitochondrial health, which is a big buzzword, uh, mitochondrial boosters, and all these other things, we do need to ground this discussion in what mitochondria are. So take it away.
- NCNav Chandel
Yeah. Tha-thanks again, Peter. I, I agree with you. I think it's not only mitochondria, but the other big buzzword is mitochondrial dysfunction, right? That's the real buzzword which you hear over and over. So if you're gonna talk about mitochondrial dysfunction, you're absolutely right. Why don't we start with mitochondrial function? Now, mitochondria do a lot of things, things, and I'm sure my colleagues will be like, "Nav, you didn't discuss X, Y, and Z." So we're not gonna discuss how mitochondria are made or degraded, uh, and how many different kinds of mitochondria there may be. There's a lot we can cover. We're gonna focus on one thing, mitochondrial function. What do mitochondria functionally do? Most people know it as the powerhouse of the cell because it makes the ATP, right? And that gives you the power for your muscles, your neurons to fire. Uh, and for a long time, um, most of us just thought about mitochondria as an ATP generator. Uh, so when mitochondrial dysfunction comes, let's say, uh, does it happen in aging or in heart failure, it's you don't ha- make enough ATP. Now, remember glycolysis can also make ATP. So you have these, but mitochondria is much more efficient and can give you a lot more, right? So very simple and all the great theories around mitochondrial dysfunction related to any particular disease if it is causal or the natural aging process is all about ATP. Well, I'm here to tell you we're not gonna talk about the ATP because there's a lot more they do. So just to back up, the electron transport chain is, is generates a, a протоmotive force, basically a voltage which can be harnessed to make ATP. That process is, is coupled to something called the Krebs cycle or the TCA cycle, and it turns out that the TCA cycle is the anabolic engine also in your cells. So mitochondria do two things. They make ATP, and they can make the building blocks, the metabolites that are the building blocks for new lipids, new nucleotides like DNA, RNA, right? Amino acids for, for the building blocks of the protein. And that's kinda set a law. You know, people forgot that mitochondria's an anabolic engine. We g- we'll get into it with cancer in a second. And so that's what classically the great biochemist of the 20th century taught us, us, and that's, like I said, it's in your textbooks, books. What has changed in the last, say, 30 years, and I think I've been part of that revolution, um, is that mitochondria also communicate, right? They're just not an organelle sitting on the side. Uh, and you know, things like mTOR, when they get activated or deactivated, mTOR is a big decision maker of metabolism. Your genes being turned on and off. They're deciding cell fate, how a cell becomes a, what it does, right? And mitochondria just sitting there giving you ATP, giving you metabolites. It has no decision-making properties. Well, that's changed.
- PAPeter Attia
Can we back up for one sec, Nav, um, and just give folks maybe a sense of size and scale? So, um, are there any cells in the body that don't have mitochondria in them?
- NCNav Chandel
Red blood cells.
- PAPeter Attia
Okay. And, um, absent red blood cells, when you consider all the other cells which have mitochondria, what is the approximate cellular density of mitochondria? So if you-
- NCNav Chandel
It depends.
- PAPeter Attia
Yeah. So let's talk about a neuron. A neuron might have approximately how many?
- NCNav Chandel
I actually, I don't know these numbers, to be honest with you. Uh, the hepatocytes are full of them. Um, but, but again-
- PAPeter Attia
But we're talking thousands.
- NCNav Chandel
Yeah.
- PAPeter Attia
We're, yeah, we're, we're-
- NCNav Chandel
Yeah, yeah, for sure
- PAPeter Attia
... maybe more.
- NCNav Chandel
Maybe more. But again, and what, instead of worrying about are they, are they dense or they're not dense, I think if you look at 'em from what they're doing, there's the ATP, there's the metabolites, but what I really wanna get into is the third aspect, uh, which a few mitochondria could probably fulfill. Well, and so that way you don't have to always think about mitochondrial biogenesis. I think that's what why you're asking this question.
- PAPeter Attia
I'm more thinking of it in terms of supply and demand mismatch, for example, right? So are they being paired to cells in density based on energy need or metabolite need? Because, for example, a hepatocyte doesn't actually need much ATP.
- NCNav Chandel
Yeah.
- PAPeter Attia
But it needs a lot of anabolic precursor.
- NCNav Chandel
Complete.
- PAPeter Attia
Right? So, so is it-
- NCNav Chandel
It makes glucose, for example.
- PAPeter Attia
Right. So I assume that in the hepatocyte, the density is optimized more towards catab or anabolism, whereas in a very energy dense cell, like a muscle cell where- ATP is probably more important than precursor to building blocks. You're optimizing around this other function of ATP generation. That, that's basically what I was asking
- NCNav Chandel
Yeah. On a, on a, on a first approximation, that's true. Although, well, because there's a third function [laughs] um, of that simple theory, uh, and I, I don't disagree with that. I, I just don't think about it anymore in those simple terms, because there's a third function that is becoming very dominant. And I actually don't know this third function I'm gonna talk about, how it fits into that paradigm-
- PAPeter Attia
Got it
- NCNav Chandel
... that you just explained, right? That, and that's why I've stopped thinking about, uh, more or less mitochondria, and that third function is that mitochondria are constantly generating signals to the rest of the cell. Uh, and these signals are very, are optimized for cellular function, right? So what are these signals? So one of them is the, the electron transport chain is not a perfect system, and it leaks electrons. It can leak a little bit of electrons or a lot of electrons to make H2O2, make superoxide first, and then H2O2. People used to think H2O2, hydrogen peroxide in cells, damaging, damaging, damaging. In fact, the oldest theory of aging says basically that as you get older, your mitochondria degenerate, and they make copious amounts of H2O2 to cause degeneration of the muscle, of the neuron.
- 7:09 – 10:43
Electron transport and reactive oxygen species: how mitochondrial energy production creates cellular signaling byproducts
- PAPeter Attia
I, I do wanna just make sure people understand how that's happening and why it's happening. I think a little bit of biochemistry won't kill someone.
- NCNav Chandel
Okay.
- PAPeter Attia
So, um, when, uh, acetyl-CoA is running through these four structures, uh, in the, these four complexes across the electron transport chain-
- NCNav Chandel
Well, it's, it's not that, right? Acetyl-CoA is part of the Krebs cycle. Uh, right?
- PAPeter Attia
Yeah, yeah, yeah.
- NCNav Chandel
So, so, right, right?
- PAPeter Attia
Yeah.
- NCNav Chandel
So just, yeah, we can get into it.
- PAPeter Attia
Yeah, yeah.
- NCNav Chandel
Yeah, we can do a little biochemistry. It's okay. So you go from glucose to pyruvate. Pyruvate comes in the mitochondria. Uh, pyruvate becomes acetyl-CoA-
- PAPeter Attia
Acetyl-CoA
- NCNav Chandel
... along with oxaloacetate to jumpstart the TCA cycle. Let's just look at that first step, the pyruvate to acetyl-CoA. Uh, it takes an NAD molecule and makes NADH. NADH is full of electrons. It goes to complex one, uh, of the electron transport chain. Complex one takes that NADH, two electrons, and makes NAD. The reason why people are so interested in NAD precursors is they're thinking their complex one is not working so well because it's not giving back the NAD to make mitochondria run, to men- generate ATP in the TCA cycle. So if I give a lot of NAD, maybe I can overcome the complex one deficit, which is found in Parkinson's, linked, and whether it's linked to normal aging is debatable, and we'll get into that. Uh, and so that NADH electrons now are gonna go down the electron transport chain with the final elecs- acceptor of those electrons being oxygen, right? So think of it as a, um, uh, the best analogy I can think of is a waterfall, right, through a tube. Um, and it's going through a tube into a tank, okay? And the tank is the, the oxygen that's accepting all that water, right? There are holes, very tiny little holes in that, in that tube, and that, that's that leak. And that leak, it can increase or decrease depending on how filled that tank is, right? If the tank is completely full, all of that water backs up, and now you get that leak happening 'cause it, it has to go somewhere, right? And, uh, a- and so that's a simple way to think about it, that the, the best analogy I can think of is, is you have this NADH, which has these two electrons, and it passes it down the electron transport chain to keep it simple, and oxygen is the final acceptor of it, right? This allows the NADH, when it passes those two electrons, it regenerates NAD, and it keeps the TCA cycle going, okay? But that electron transport chain isn't perfect. Not every electron always gets to oxygen. There's a little bit of imperfection, a little bit of leak, and that one electron can take oxygen to s- something called superoxide, which becomes quickly converted by some enzymes called superoxide dismutase to make H2O2. So what people thought is, well, the electron transport chain, this slightly imperfect system, becomes more imperfect. So now it's leaking more electrons in neurodegeneration, in cancer, in everything, and now it's making copious amounts of H2O2.
- PAPeter Attia
And is there evidence, by the way, Nav, that even in an absent disease state, as a person ages, as they go from 10 to 20 to 30 to 40 to 50 to 60, what is, what we represent in the textbook, which is the final output after you've transferred all of the electrons-
- NCNav Chandel
Right
- PAPeter Attia
... and made all of the ATP, you have two outputs, carbon dioxide and water, which is what we are all breathing out.
- NCNav Chandel
Coupled to generating ATP.
- PAPeter Attia
Yep. And is the idea
- 10:43 – 18:42
Oxidative stress and aging: defining antioxidants and antioxidant systems, and the limits of supplementation
- PAPeter Attia
that absent disease, just aging, increases the fraction of H2O2 relative to just H2O?
- NCNav Chandel
I don't think so.
- PAPeter Attia
Okay. Interesting.
- NCNav Chandel
I, I think this-
- PAPeter Attia
Anyway, I wanted to go through this just so people understand what H2O2 is relative to the normal process of H2O.
- NCNav Chandel
Right. What you're asking me is, uh, in a normal person, does the system become leaky?
- PAPeter Attia
Just by age.
- NCNav Chandel
Just by age. I don't think so. Uh, all right? I think this is one of the new paradigms. It's not written in stone yet, but this is what we've been working on. And not only that, but let's back off. To begin with, do we make copious amounts of H2O2, oh, to levels that become toxic? I don't think so.
- PAPeter Attia
Okay. And the way we got onto this-
- NCNav Chandel
Because, because we have a lot of antioxidants, Peter, that keep that in check. And if anything-
- PAPeter Attia
Explain to folks what an antioxidant is, 'cause I-
- NCNav Chandel
It's, it's, it-
- PAPeter Attia
We're taking it for granted as we say this
- NCNav Chandel
Yeah, yeah, yeah. So it's just, it's, it's a protein that can detoxify different molecules of reactive oxygen species. So there's a, there's an, uh, there's a s- family of proteins called superoxide dismutases. They take superoxide and make H2O2. H2O2, when you make it, has three choices. First choice, which is, it's, it's, almost happens, is because we're full of proteins that degrade it to water. So there's two classes. One is catalase, is the other one is peroxiredoxins, and we're full of ro- they really have high reactivity to it, and they convert it to H2O, right? So we have a system-
- PAPeter Attia
And, and sorry, I, no, I just, I keep interrupting you-
- NCNav Chandel
Yeah, yeah, yeah
- PAPeter Attia
... but I just-
- NCNav Chandel
That's okay
- PAPeter Attia
I don't want people to lose the, the thread H2O is a very stable molecule.
- NCNav Chandel
Very stable molecule.
- PAPeter Attia
Okay, so you have oxygen. It has these covalent-
- NCNav Chandel
Yep
- PAPeter Attia
... bonds to hydrogen.
- NCNav Chandel
Very stable.
- PAPeter Attia
You have a couple electrons that can-
- NCNav Chandel
Yeah
- PAPeter Attia
... create polarity, but why is it not reactive in a way that H2O2 is reactive?
- NCNav Chandel
Because it can, it's H- actually, H2O2's not that reactive. Superoxide is super reactive. Uh, uh, but there are cysteines which can readily get oxidized, uh, is by H2O2. Ooh, and that's part of the second thing that I was gonna talk about, which is the cysteine on certain proteins, and we don't quite know the code of that still. Oh, that, that changes is the activity of that protein, and that's all signaling, eh. That H2O2 with iron can undergo a Fenton reaction to make hydroxyl radical. Doesn't last long, um, and is super toxic. It'll react with anything that it touches. That can, with a polyunsaturated fatty acid, can make something called lipid peroxide and start a chain reaction, which is now called ferroptosis. It's a new form of cell death discovered about 12 years ago. Start-
- PAPeter Attia
So the more we create H2O2, the more we theoretically risk this process.
- NCNav Chandel
The ferroptosis process. Yes, exactly. So you make the H2O2, lots of proteins to get rid of it. You always need a little bit, we think, think, for that signaling, that cysteine oxidation. But if you overwhelm these antioxidants for whatever reason, and, you know, for some reason the antioxidant capacity goes down, you start to push that not only for the signaling, but you start to push it, uh, towards this ferroptosis.
- 18:42 – 23:48
Mitochondrial signaling: metabolites, epigenetic regulation, and immune activation beyond ATP
- NCNav Chandel
and everything, and-
- PAPeter Attia
All right. So let's go from function to dysfunction
- NCNav Chandel
Can we just go back to function? 'Cause I only talked about one of the, uh, H2O2.
- PAPeter Attia
Oh, sure, sure.
- NCNav Chandel
Uh, uh, there's a lot of them. Let me just give you two more-
- PAPeter Attia
Yep
- NCNav Chandel
... just to, which are important for this discussion. Uh, the second one is metabolites. So those TCA cycle metabolites that are linked to electron transport chain, including acetyl-CoA you just mentioned-
- PAPeter Attia
Alpha-ketoglutarate
- NCNav Chandel
... alpha-ketoglutarate.
- PAPeter Attia
Right, yep.
- NCNav Chandel
So it turns out that protein acetylation, when proteins get acetylated at lysines, is a way to change their function. And a s- lot of acetyl-CoA comes from mitochondria. So you could see how mitochondria controlling acetyl-CoA levels-
- PAPeter Attia
Which m- co- probably one of the three most important things that drives autophagy is acetylation of protein.
- NCNav Chandel
Yeah, well, the big one is also in the histones being acetylated-
- PAPeter Attia
Yep, yep
- NCNav Chandel
... to keep a chromatin open or closed, uh, right? That mitochondria control. So that's a signaling aspect of mitochondria now. Has nothing to do with ATP, right? Alpha-ketoglutarate. So there's 75 enzymes called the alpha-ketoglutarate dioxygenases. They use oxygen and alpha-ketoglutarate, okay? They use iron, Fe 2+, uh, s- and they make succinate, okay? Uh, to recycle that iron, you need vitamin C to make them functional. So when you don't have enough vitamin C, those enzymes aren't working. So let's just go through those. So now, again, you have alpha-ketoglutarate as an input from mitochondria into running 75, I would argue, some of the most important enzymes. So the enzymes that cause DNA methylation to be, uh, DNA demethylation are alpha-ketoglutarate. Histone demethylases. The collagen prolyl hydroxylases, so y- you and I hopefully have good skin as we age, age, are alpha-ketoglutarate dioxygen- in fact, the vitamin C that people like to put on their skin, I always argue, is because you keep the collagen prolyl hydroxylases from working properly, uh, right? Uh, so, so now you have, you know, think about it, your DNA demethylation and, right? If your DNA's hypermethylated, you typically turn off genes, right? Uh, so the epigenetic clock phenomenon, and I think you've discussed a lot about [laughs] uh, whether it's of any value or, you know, and I'm not gonna debate that, right? But all I'm gonna say is that people who are so into their epigenetic clocks, alpha-ketoglutarate is controlling those clocks because they're needed to keep the demethylase reactions going properly. Uh, so now you have a s-
- PAPeter Attia
Okay, so that's our second major, major function.
- NCNav Chandel
So H- right, so you have H2O2, you have TCA cycle metabolites controlling essentially epigenetics. Your third one is, so mitochondria has its own DNA and RNA. If it spills out, the same sensors that look at pathogens, so, you know, we have s- things that say, "I'm infected with a pathogen. I have to turn on a cytokine." Well, the mitochondria's your bacteria, right? It, uh, you know, the current theory of how we have a normal s- you know, a, an, a eukaryote is an archaea, which is, which is not a bacteria, it's a kingdom by itself, and alpha proteobacteria. The two of them had a symbiosis, is, as before oxygen was around. And, and so there's a bacteria within us.
- PAPeter Attia
Yeah.
- NCNav Chandel
Uh, s- and if that bacteria releases its DNA or its RNA, it's, it's viewed as a foreign, and the same inflammation pathways-
- PAPeter Attia
And sorry, why is it that we didn't thymically be ex- why were we not exposed to that in the early, uh, w- w- yeah, basically, why did our thymus not account for that? 'Cause there must have been some disruption of mitochondria-
- NCNav Chandel
Yeah
- PAPeter Attia
... during embryogenesis.
- NCNav Chandel
Great, great question. Actually, I don't know the answer to that. Uh, but, you know, um, o- one thing could be that some of those antigens are not presented, uh, because, uh, they're not as easily presented because they're hidden and because they're in the mitochondrial matrix, right? Uh, but the key point, um, um, just to sort of wrap this up, I mean, there's many other things that, that, that mitochondria release, okay? And, and again, to the listeners especially, my colleagues, as just in the interest of time, um, uh, we're gonna, for our discussions, we're gonna keep at least three of them. There's many more. One is H2O2, hmm, needed for immune function as we've he- needed for cell differentiation. Alpha-ketoglutarate, which we wanna talk about later in the supplement section, and keeping the epigenetics going in a proper way. And lastly, sometimes mitochondrial DNA or RNA being released is to turn on immune function. And again, like with immune function, if it's chronic, you know, some people think, think it's not your ATP, uh, Peter, you asked whether, uh, it's, it's decreasing with age or H2O2 increasing. Could it be we just have leaky DNA from mitochondria?
- PAPeter Attia
But why is that a good thing, Nav? Because if-
- NCNav Chandel
No, no, no, I'm not saying, chronically leaking is not a good thing, right?
- PAPeter Attia
No, no, but I'm saying any, y- you mentioned earlier that if, if the mitochondria
- 23:48 – 28:18
How mitochondrial DNA and RNA can activate immune pathways and whether chronic low-level leakage contributes to long-term inflammation and aging
- PAPeter Attia
releases its DNA and/or RNA, it's gonna activate the immune system because it's not identified as self. And but that activation of the immune system is very specific.
- NCNav Chandel
Right.
- PAPeter Attia
So what is it targeting besides the-
- NCNav Chandel
Right
- PAPeter Attia
... the DNA and RNA of the mito?
- NCNav Chandel
There's two big questions in that field. How it gets released It's not known
- PAPeter Attia
It's not mitophagy or-
- NCNav Chandel
People argue that improper mitophagy might release it or the normal turnover, fission fusion. And where H2O2, we know how it's released. Alpha-ketoglutarate has actual, um, transporters. This one is a bit of a black box. Uh, uh, but once it's released, we know the targets, cGAS, STING, and mAbs for the RNA. So there's, there's dedicated immune-
- PAPeter Attia
And what do those T cells go and do? Who do they turn their ire on-
- NCNav Chandel
Well, they can ma-
- PAPeter Attia
... once they're activated?
- NCNav Chandel
Right. They can w- well, not only T cells, but any, any cell can release it, and the, the signals they release are type one interferons, as which can then orchestrate the whole immune system. But I think the question you're asking is, is this a regulated system?
- PAPeter Attia
And is it for a net positive? In other words-
- NCNav Chandel
Right
- PAPeter Attia
... is this something we are doing to amplify an immune response? So if a virus comes in you, if influenza comes along and attacks the endothelium or the epithelium rather of your throat, is it also something that the immune s- that the mitochondria do say, "How can I participate and help the organism? I'm gonna release RNA and DNA. It's going to make more interferon. It's gonna make more T cells, more B cells." Uh-
- NCNav Chandel
Right. Right, right
- PAPeter Attia
... f- is that, is that the, the theory?
- NCNav Chandel
That, absolutely. In fact, um, uh, people have done those sort of studies. They've, they've, they've taken different viruses. I did one, uh, and, uh, helped a colleague at Northwestern where they did poxviruses, you know? Good old poxviruses. It's, and lo and behold, mitochondrial DNA gets released. It used to turn on exactly what you're saying. And, and that-
- PAPeter Attia
What's the signal? Well, how does it know to do that?
- NCNav Chandel
Yeah, exactly. So this is the b- so we, so the mitochondrial DNA, it, so compare, if I had to compare H2O2 versus the DNA, H2O2 is still a black box what it hits. Which proteins, which cysteines to, uh, right? We know how to manipulate. Mitochondrial DNA, we know, uh, the receptors it's gonna hit. We just don't, I don't think, again, people might argue, I don't think we have a good explanation how it gets out. And if we knew if there was a select transporter or something that we can manipulate and maybe even make drugs against it, uh, depending on what you wanna do. But what I was gonna get at is, you know, you have this mitochondria with two membranes, is I could imagine, Peter, a scenario where you're making enough H2O2, y- you're making enough ATP, you're making enough TCA cycle metabolites like alpha-ketoglutarate, so everything is great. Uh, but you know what's not great? Is maybe the membranes are not perfect and they're leaking a little bit of mitochondrial RNA or DNA, right? Uh, and by releasing a little bit of mitochondrial RNA or DNA over 20, 30 years is causing a little bit of an immune response, a little low-grade inflammation all the time. You know? So some people think maybe the autoimmunity that you get as you age or the inflamma-aging might be of leaky mitochondria. Not enough that it compromises DNA, not that it compromises alpha-ketoglutarate or even my beloved H2O2 signaling, but it just sort of leaks out, uh, at low levels, and that's the, the increase in, in inflammation that we're seeing. It's a hypothesis. It's difficult to test because we don't, what you, exactly what you pointed out. How does it get out? Because if I knew how it got out, I could then come in and stop it in a mouse model or whatever and say, "Look, here's the aging infl-"
- PAPeter Attia
But, but do you know-
- NCNav Chandel
"... inflamma-aging, and now it's not happening," right?
- PAPeter Attia
Yeah. S- sorry, sorry to interrupt.
- NCNav Chandel
Yeah.
- PAPeter Attia
Do, do you know, Nav, that it gets out of a cell that remains? Or does getting out imply that that particular mitochondria, that organelle was destructed and it's binary? Anytime DNA and RNA get out, it means that particular organelle is gone versus this idea of a leaky organelle.
- NCNav Chandel
Right. You hit it on the thing. This is my-
- PAPeter Attia
We don't know that. We don't know that.
- NCNav Chandel
We don't know. Th- well, this is my problem with, with, with the, the, the idea. I've always assumed then that, uh, you know what? We forgot to, actually, this is perfect
- 28:18 – 29:35
How mitochondrial release of cytochrome c can trigger cell death or stress signaling
- NCNav Chandel
segue. We for- I forgot to mention the most important e- experiment done in signaling, uh, by Zhadong Wang, which got people like me inspired in the mid-'90s to think of H2O2 and other things, which was that he showed that cytochrome c, which is part of the electron transport chain, part of electrons flowing, making ATP, if it gets out from the mitochondria, that cell goes on to die. That is the death, the mammalian death signal is cytochrome c getting released. Now, there's something called where cytochrome c can get a little released and the mitochondrias can repair itself. Many people think the mitochondrial DNA must be doing that. So in other words, it's not doing cell death. When I first saw it, it's like, I was like, "The cell's about to die. It's just turning on inflammation," exactly on first principles. But it looks like there's improper p- maybe permeabilization or some leaky mechanism I don't understand. And I'm, I, I actually struggle with it at how does it really work, right? Because to me it would seem binary, but people argue now that cytochrome c even, which is binary, uh, that there is cytochrome c a little bit gets released and then it can repair itself of, and it's turning on stress signaling. So more to be discovered on that front.
- PAPeter Attia
So let's put a bow on this because
- 29:35 – 34:10
Mitochondrial dysfunction: survival without mitochondrial ATP production, glycolytic compensation, and the central role of cellular signaling
- PAPeter Attia
the two biggest and most obvious things that the mitochondria does, which is generate ATP-
- NCNav Chandel
Right
- PAPeter Attia
... anything that interrupt, anything that interrupts that significantly is incompatible with organism life.
- NCNav Chandel
That's not true.
- PAPeter Attia
I mean, cyanide, right? If you interrupt-
- NCNav Chandel
Oh
- PAPeter Attia
... that process, we, we do- we're done, right? If you stop making ATP, you're dead, right? That's what I mean.
- NCNav Chandel
So the cyanide one is an interesting one, uh, because if you do it, these experiments genetically, so cyanide binds to cytochrome oxidase. It's, it's, um, and, and so does carbon monoxide and many other things. But if we genetically, in a heart Okay? Or in a dopaminergic neuron. And you would both, you and I would both, or even in a muscle. Three bioenergetically heavy things.
- PAPeter Attia
Yep.
- NCNav Chandel
There are signaling pathways such as activation of AMPK, which can turn down mTOR. Or that cell lives fine for months and months and months and is on glycolysis.
- PAPeter Attia
So you're saying it's not that it evolves a way around that particular complex within the mitochondria. It's very interesting.
- NCNav Chandel
Yeah.
- PAPeter Attia
Why is it-
- NCNav Chandel
And by the way, here's a, here's a crazy thing. A colleague of mine at Northwestern had knocked out components of the electron transport chain. The heart continued to pump on glycolysis.
- PAPeter Attia
For how long?
- NCNav Chandel
Months. And then, but you know what happened? All this signaling that I'm talking about, and he doesn't understand all of it, but that signaling caused it to hypertrophy, and now it can't contract and the mouse dies.
- PAPeter Attia
But why is it, then-
- NCNav Chandel
And by the way, can I just-
- PAPeter Attia
... that cyanide is so lethal in seconds? Why can't the organism survive on glycolysis for a long, a while?
- NCNav Chandel
I think because when you, when we genetically do it, it, it... And by the way, I actually don't know why we, which organ failed. So the ones that we've done, right, we don't actually know. Uh, same with rotenone, which is a complex one inhibitor linked to Parkinson's, right? So if we do the same experiment in dopaminergic neurons, as those neurons basically, uh, live off glycolysis for three months in a mouse, uh, s- and then the neurons start to die. But during those three months, they stop making dopamine, ain. Right? So in other words, they have enough energy to live, but not to be functional.
- PAPeter Attia
So I'll take, I'll take my extreme statement back.
- NCNav Chandel
So, so it's not about death. It, it, it's import-
- PAPeter Attia
It's just, it's profound dysfunction. So, so but fun-
- NCNav Chandel
But, but, but it's dysfunction.
- PAPeter Attia
Yeah.
- NCNav Chandel
And but the question is why is that dysfunctional?
- PAPeter Attia
Yeah. So but clearly, top hierarchy function of mitochondria make ATP. Another big function of mitochondria is make metabo- metabolic building blocks.
- NCNav Chandel
Right.
- PAPeter Attia
Right. And then the third one I'm calling 3A, 3B, 3C, and those are the three things you just talked about, right?
- NCNav Chandel
H2O2.
- 34:10 – 41:48
How to assess one’s mitochondrial function
- PAPeter Attia
In a person listening to us or watching us who wants to know how well their mitochondria function [sighs] , what, what test can they do? I mean, I, I have my favorite, but I want to know yours.
- NCNav Chandel
Okay. I have none.
- PAPeter Attia
You have none?
- NCNav Chandel
I have none without taking a biopsy.
- PAPeter Attia
All right. Well, tell me if you do a biopsy, what you're going to do. What are you going to look at? You're gonna, where are you going to biopsy, the muscle?
- NCNav Chandel
Exactly.
- PAPeter Attia
Okay. See?
- NCNav Chandel
I don't know.
- PAPeter Attia
What, what assay can you do in the lab?
- NCNav Chandel
You can do metabolomics. That'll tell you your TCA cycle metabolites are up or down in a snapshot. It's not perfect. You can, uh, take those and do isolated mitochondria, and you can look at maximal efficiency. I don't know how useful that is because here's the reason. What human genetics has taught us from mitochondrial mutations, so you know, the people who have genetic mutations either in their DNA, their nuclear DNA or their mitochondrial DNA, which causes their proteins to be dysfunctional in their mitochondria, uh, and you have to lose 70% of mitochondrial protein function.
- PAPeter Attia
It's that redundant.
- NCNav Chandel
It is that much excess capacity. So if I-
- PAPeter Attia
Well, that makes sense. I mean, if you're going to have something that is that critical to life.
- NCNav Chandel
Right? So you and I start, let's say, at 100%.
- PAPeter Attia
Yep.
- NCNav Chandel
And you can go all the way down to 70 and 80% in almost every tissue before-
- PAPeter Attia
20 to 30, you mean.
- NCNav Chandel
Yeah, yeah.
- PAPeter Attia
Yeah, yeah, yeah.
- NCNav Chandel
With 20 to 30, sorry, left.
- PAPeter Attia
Yeah, remaining. Yeah.
- NCNav Chandel
That are remaining. So here's the analogy. You're a car guy, remember. Right? Uh, uh, so we're going to use the good old Aston Martin because I like James Bond, okay? The last one in No Time to Die, I think in the last movie, that Aston Martin, I looked it up, uh, yesterday, 217 miles an hour. My favorite one, the classic 1964 James Bond [chuckles] and the Goldfinger one, goes about 140 miles an hour. Now, you could look at those two and say, "I don't want this one, man. This one's not, this, uh, this is..." In the city of Chicago, you can only drive 50.
- PAPeter Attia
Yeah.
- NCNav Chandel
It's just not rate limiting.
- PAPeter Attia
Yeah.
- NCNav Chandel
That's the best way to think of it. So when you're measuring it, how do you figure out it's rate limiting?
- PAPeter Attia
Okay. Well, let me con-
- NCNav Chandel
And-
- PAPeter Attia
... extend your car analogy then.
- NCNav Chandel
Okay.
- 41:48 – 47:52
The role of VO2 max and mitochondrial efficiency in maximizing your marginal decade
- PAPeter Attia
mitochondria.
- NCNav Chandel
But, but, but let's go back to my Bond analogy. A, as I age, do I need to have fuel efficiency, all of that, even like the James Bond 1964 car? Probably not.
- PAPeter Attia
It depends on how much physiologic reserve you wanna have. Because at some point, I mean, using VO2 max as an analogy, okay. So, um, uh, let's assume I measured your VO2 max today and it was 42, right? That would pro- I don't know, uh, I don't have a nomogram in front of me, but I bet that would put you in the top quartile for your age.
- NCNav Chandel
Yeah.
- PAPeter Attia
Okay. That number's going down at about 10% per decade.
- NCNav Chandel
Yeah. Yeah, yeah, yeah.
- PAPeter Attia
Now, there is a point beneath which Uh, meaning there was a VO2 max point that once you go below that-
- NCNav Chandel
Right
- PAPeter Attia
... it impacts daily living.
- NCNav Chandel
Right.
- PAPeter Attia
Now, that depends on what you define daily living as. For Peter Attia, that number is about twenty-eight to thirty.
- NCNav Chandel
Right.
- PAPeter Attia
Once my VO2 max falls below twenty-eight to thirty milliliters per kilogram per day, my quality of life will suffer dramatically.
- NCNav Chandel
Right.
- PAPeter Attia
For some people, that number is twenty, but for virtually every human on this planet who wants to live independently, that number is about fifteen or sixteen. So the argument I would have is everybody should have as high a VO2 max as possible to give them as much optionality as posi- as possible in the inevitable state of decline. And I think that is true for mitochondrial function.
- NCNav Chandel
Two points. Going back to the, the car analogy, a, a, you want to go at least -- you should be able to go forty-five, fifty miles an hour. If you have a car that's below that, that's not a functional car even in the city of Chicago.
- PAPeter Attia
Well, not only that-
- NCNav Chandel
Right?
- PAPeter Attia
... you don't want to be at the red line going forty-five to fifty miles per hour.
- NCNav Chandel
You don't want to be at the red line to begin with-
- PAPeter Attia
Yeah
- NCNav Chandel
... because it's gonna go down to twenty. Violent agreement on that, okay? My point is I am not convinced whether mitochondria, okay, to go two hundred miles an hour, yes, as you need more efficient mi- but whether mitochondrial function-
- PAPeter Attia
Ah, I agree with you
- NCNav Chandel
... becomes rate limiting-
- PAPeter Attia
I, I agree with you. I don't, I don't know that.
- NCNav Chandel
I don't know that.
- PAPeter Attia
I don't know that.
- NCNav Chandel
Right. So, so you made the analogy.
- PAPeter Attia
Yep.
- NCNav Chandel
You know, now if you can go a hundred miles, but we want you to go two hundred miles now, and guess what? We're gonna boost your mitochondria to do that.
- 47:52 – 54:57
Mitochondrial dysfunction and aging
- NCNav Chandel
but not the mitochondria or the mitochondria extraction, but not the delivery of-
- PAPeter Attia
All right. So let's, let's pivot and now talk a little bit about dysfunction. And let's talk about it in the broadest sense we can, which is do we believe that mitochondrial dysfunction is an inevitable consequence of aging, given that it is designated as one of the OG hallmarks of aging?
- NCNav Chandel
I am skeptical. Yeah. So a few times I'm gonna bring up conflict of interests. I think it's important to say your conflict of interest. It is almost a conflict of interest for me to say that, right? If I want to make a living, I should tell people mitochondrial dysfunction is why you're aging, and, and lots of people do. I'm not so sure. F- Again, not in a diseased person. We can talk about-
- PAPeter Attia
Yep
- NCNav Chandel
... the disease. We're talking about a normal, healthy person.
- PAPeter Attia
Let's talk about you and I.
- NCNav Chandel
And let's talk-
- PAPeter Attia
We're old men now, right? Relatively speaking. We're, we're-
- NCNav Chandel
I'm in my 50s [laughs]
- PAPeter Attia
... 10 years older, we're 10 years older than-
- NCNav Chandel
You're older than our eastern listeners
- PAPeter Attia
... than when we first met. Okay? Yeah.
- NCNav Chandel
No, I, I agree. The question is, uh, is, uh, going back to this analogy, if, if you have to go to 70, 80% of your efficient mitochondria for it to have, have a cell not work properly, do you ever get to that? The hallmarks are, by the way, they're instructive, but they're misleading. Like, all the hallmarks. They are what's called a sufficiency experiment, right? It's wh- what does that mean? That means if I take a mitochondria, hmm, and I perturb it, so healthy mitochondria is this high, and I make it here in a particular organ or an organism, it will degenerate and l- and maybe it'll age or look like aging. You could do it with a lysosome. You can make lots of cells senescent and, right? But that doesn't mean that normal aging, Ing, that's what happens, right? In other words, does mitochon- Is mitochondrial dysfunction necessary for normal aging? Ing, it might be sufficient. So people have done what's a sufficiency experiment, all right? Right? Which is they take mitochondrial DNA, and they cause mutations in them genetically. So the mouse gets mutations only in their mitochondrial genome. People have done it with the nuclear genome, and both of them age. I can tell you the nuclear, the new nuclear genome, hmm, mutations looks more like normal aging. Mitochondrial ones that they've generated, in normal aging we'll have this much mitochondrial mutations, let's say. You have to go almost tenfold higher mutations in order to start to see that organism degenerate in a mouse. S- And it doesn't even look like a normal aging.
- PAPeter Attia
So let me make sure I understand that and replay it back to our listeners.
- NCNav Chandel
Yeah.
- PAPeter Attia
Um, w- we're talking about something that we're taking for granted. I'll just state it quickly. Um, we have two genomes. We have a genome within the nucleus. That's the one we are almost always thinking about.
- NCNav Chandel
Right.
- PAPeter Attia
But then the mitochondria have their own DNA.
- NCNav Chandel
Right.
- PAPeter Attia
And we should just make sure everyone understands that. Okay. If you take the DNA in this cell, what we're calling the nuclear genome, and you apply mutations to it, because as we age, we are acquiring mutations-
- NCNav Chandel
Absolutely
- PAPeter Attia
... you are, you're saying you are able to replicate an aging phenotype by adding mutations to the nuclear genome.
- NCNav Chandel
Not me. This is the work of others in the field.
- PAPeter Attia
Yes, yes, yes, but yeah, yeah.
- NCNav Chandel
To be very clear, none of this-
- PAPeter Attia
Yeah, yeah, yeah
- NCNav Chandel
... is, but, but, but people-
- PAPeter Attia
The field is. Yeah.
- NCNav Chandel
Yeah, they've got some mouse m- the new mouse models where you have some nuclear, uh, DNA mutations at the same level as a normal aged mouse would.
- PAPeter Attia
Yep.
- 54:57 – 1:07:50
Metformin mechanisms: gut accumulation, complex I inhibition, and indirect effects on metabolism and exercise
- NCNav Chandel
defects.
- PAPeter Attia
So there are so many compounds I want to talk with you about. Um, can we, can we turn to metformin as the starting place?
- NCNav Chandel
Yeah.
- PAPeter Attia
Okay. So, um, you're one of the people who knows more about metformin than almost anybody. Um, uh, you know, listeners of this podcast have heard me talk about metformin quite a bit. I've done many podcasts on it. I've had Nir Barzilai on at least twice. I've also been on Andrew Huberman's podcast where I did a very, very thorough journal club looking at both the Banister paper and the Keys paper, which were really the two massive epidemiologic studies. Uh, the Banister paper was the one that really got people excited about metformin as a geroprotective agent. This is the study that looked at a cohort of the population and made an observation that non-diabetic people who took metformin had, um, wor- pardon me, non-diabetic people not taking metformin had worse outcomes than diabetic people taking metformin when it came to cancer. That basically got the idea going that metformin could be protective of cancer.
- NCNav Chandel
Yeah.
- PAPeter Attia
Roughly eight years later, a more, in my opinion, rigorous study came out that challenged those findings, ran the analysis two ways, with and without a statistical tool used by the first analysis, and it didn't find that at all. And, and truthfully, I found the second study more convincing.
- NCNav Chandel
Right.
- PAPeter Attia
That doesn't mean metformin doesn't work. It just means that the epidemiologic argument was more shaky.
- NCNav Chandel
What about the Phase III clinical trial in breast cancer that failed?
- PAPeter Attia
Yeah, and then the prostate cancer trial.
- NCNav Chandel
That one had some signal.
- PAPeter Attia
So let's talk about them. Let's, let's talk about them. So, um, give folks a little-
- NCNav Chandel
But I, but I agree-
- PAPeter Attia
But people-
- NCNav Chandel
But I agree with what you just said, by the way.
- PAPeter Attia
Yeah. So, so people have heard of metformin. I don't think there's anybody listening to us that hasn't, but I don't think a lot of people maybe understand the complexity of that drug and how many different things it does. So can you-
- NCNav Chandel
Yeah
- PAPeter Attia
... can you just explain to people how metformin works?
- NCNav Chandel
Yeah. [laughs] Well, again, working progress.
- PAPeter Attia
To the best of our knowledge. Yeah, yeah.
- NCNav Chandel
[laughs] Um, so l- let's just-- I think, uh, you and I have talked about this before. Let's just talk about any of the supplements we'll go through or any of the drugs. Most of them, you take oral. Let's stick with that. The first pass is the gut, right? So with metformin, and it goes in the gut, and people have done this with C11 PET imaging. They can see the gut light up, right? The intestines, the colon light up. Then it goes through the portal vein to the liver. Then it goes, there's the kidney, and then it gets excreted out in a couple of hours, right? It doesn't get in the brain. It doesn't get in the heart. It doesn't get in the muscle at appreciable levels. Why is that? Because metformin needs a transporter, the organic cation transporters. There's one, two, and three. There's some other ones as well, but let's just keep it simple. Well, the gut ends up taking it up quickly, but releasing it in the portal vein slowly. So the highest concentration of metformin, up to a millimolar, wow, is in the gut. By the time it gets to the liver, it's less, fifty micromolar, a hundred micromolar max, right? By the time it's in the blood, uh, ten micromolar. We have seen some immune cells, macrophages and T cells, certain types, and other people have noticed that they will also take it up. That you can't have the resolution, uh, when you do a, a, a PET imaging, yeah, analysis. But, but this part is really key, and it's gonna explain the cancer data in a second as well. You need the transporters. So the highest concentration is in the gut.
- PAPeter Attia
And everything after the gut, um, is-- So, so when the gut absorbs the vasculature of the gut, so the gut has the transporter, obviously.
- NCNav Chandel
Yeah.
- PAPeter Attia
But does it otherwise diffuse into the portal circulation, or does it also require the transporter in the portal circulation?
- NCNav Chandel
It, it requires it to take it up. It needs a transporter to dump it out of the enterocytes. So the metformin gets accumulated in the intestine or the choline cells. Those, and but it takes a little bit longer or less transporters to release it into the portal vein.
- PAPeter Attia
'Cause that's a huge drop, to go from one millimole to fifty micromole-
- NCNav Chandel
Yeah
- PAPeter Attia
... is a twenty x drop.
- NCNav Chandel
It's, it's, it's estimated as high as one millimole-
- PAPeter Attia
Yeah, yeah. But, but-
- 1:07:50 – 1:12:48
Metformin and aging: does metformin provide true geroprotective benefits beyond glucose control?
- PAPeter Attia
To me, the, the, the really important question is, are there geroprotective benefits-
- NCNav Chandel
Right
- PAPeter Attia
... to metformin? So, so-
- NCNav Chandel
So let's go through those
- PAPeter Attia
... let's examine the state of the-
- NCNav Chandel
Yeah
- PAPeter Attia
... science on that.
- NCNav Chandel
Right. So if you take metformin at the time you're having a meal, and we've seen this in our experiments, and it's the postprandial. After eating a meal, you have a glucose spike. I'm sure people with glucose monitors can see that spike. It depends on what kind of meal. Well, metformin abrogates that, and that's, again, complex I dependent, right? So there's pretty good data to suggest that all-cause mortality is somewhat linked to those spikes. I mean, there are some studies out there.
- PAPeter Attia
But acarbose does the same thing.
- NCNav Chandel
Yes, it does.
- PAPeter Attia
And acarbose did extend life-
- NCNav Chandel
Life
- PAPeter Attia
... in the ITP.
- NCNav Chandel
Richard Miller's r-
- PAPeter Attia
But metformin did not. Both were delivered in the chow.
- NCNav Chandel
Yeah.
- PAPeter Attia
So why do you think acarbose, which clearly does that, and metformin, which might do that, didn't work?
- NCNav Chandel
Yeah, I, I don't have a good explanation to it. Not that that was being measured, right? They didn't have glucose monitors. But I would argue that now that we can clearly see this glucose spike happening, that lots of people observe and metformin can abrogate it, I wonder if that's a good tool for people to use. I don't know what you think of that. I'm just thinking aloud, right? You have a glucose monitor, or you do it for three months. You get a good, good increase, decrease. You get, you know, some idea.
- PAPeter Attia
Well, I mean, I think-
- NCNav Chandel
And now you're on metformin
- PAPeter Attia
... so, so look, there were two glucose regu- there were three glucose-regulating drugs that went into the ITP, right?
- NCNav Chandel
Right.
- PAPeter Attia
There was canagliflozin-
- NCNav Chandel
Mm-hmm
- PAPeter Attia
... acarbose, and metformin. And the way the ITP is designed, the drug is always in the food.
- NCNav Chandel
Right.
- PAPeter Attia
So the, the vehicle of delivery is always the same.
- NCNav Chandel
Right.
- PAPeter Attia
Canagliflozin and acarbose worked.
- NCNav Chandel
Worked.
- 1:12:48 – 1:25:25
Metformin and cancer: why most cancer trials have failed, and how its efficacy depends on tumor-specific uptake
- NCNav Chandel
way. But, but the second thing, thing is cancer, which is where you started.
- PAPeter Attia
Right. So let's, let's talk about that.
- NCNav Chandel
So let's talk about that. So it's failed We can both agree on that. On clinical trials-
- PAPeter Attia
Yeah
- NCNav Chandel
... reanalyze it. There's always some signal here and there. So the prostate one, and there was a subset of patients that it, it, it, it looked pretty good, but generally, let's just say it's a negative. So why is it a negative? So we did an experiment mechanistically where we took a cell, cells that were very sensitive to metformin, and uh, and we put it in a mouse. The tumor grew. We gave the mouse metformin. The tumor shrank. In that tumor, we put that yeast NDI1 back in so it would be refractory. And guess what? The tumors came back. So again, mitochondrial complex I inhibition and by metformin and explains the, the anticancer effects. I think that part is more widely accepted. Now, we in-
- PAPeter Attia
What was the, what was the, uh, cell of origin of that cancer?
- NCNav Chandel
That was, we did it in two. We did it in a lung cancer, and we did a, a colon cancer. But, but here's the thing.
- PAPeter Attia
And how, and the metformin was delivered orally in both cases?
- NCNav Chandel
Orally. Again, orally, both cases in the drinking water.
- PAPeter Attia
So how do you think it, how do you think it made its way into the lung cancer?
- NCNav Chandel
Yeah, I'm gonna tell you in a second. So what we had noticed was not only we, many people had noticed that if I took 60 cell lines, 10 cell lines, one or two would respond in culture.
- PAPeter Attia
Yep.
- NCNav Chandel
The other 10 wouldn't care. I could go to 100 millimolar. They wouldn't care barely. So, um, a, um, a, a student in the lab, Kartik Vasan, he did a simple screen. He took a very sensitive cell line to metformin in culture, or the same one in vivo that in a mouse reduced, and he added metformin to it. And it, and it killed that cells. Okay? He added at a dose. It killed it. He basically using CRISPR, right? So, uh, uh, the CRISPR technology to knock out every metabolic gene. So he's got 3,000 different clones now with all the metabolic genes knocked out. 2,000 of them, like 1,000 of them are, are, are so fundamental for life, they die.
- PAPeter Attia
Incompatible.
- NCNav Chandel
Incompatible. The other, I don't know. I don't remember what the numbers were. Let's say there was 1,000 that lived. And, and then he asked, "If I give those metformin, who lives?" One guy lived. One, one, one clone lived.
- PAPeter Attia
One guy could live.
- NCNav Chandel
It, it lost the organic cation transporter.
- PAPeter Attia
So it couldn't bring metformin into-
- NCNav Chandel
The plasma membrane transporter, if you lose it, it laughs at metformin. It doesn't care. Okay. Why is that important? Wouldn't it be nice to do a clinical trial based on whether you're positive for that transporter or not?
- PAPeter Attia
Do we know in the, when we screen human cells, can't we screen for that cation at least in the... I mean, that should be knowable.
- NCNav Chandel
Y- y- sh-
- PAPeter Attia
Do we not know? There's, there's three of these transporters, aren't there?
- NCNav Chandel
Three transporters. Yeah, yeah, yeah.
- PAPeter Attia
Do all three of them transport metformin equally?
- NCNav Chandel
Um, uh, seems like at least in the cancer one is organic cation transporter three.
- PAPeter Attia
Okay.
- NCNav Chandel
Eh, eh, but, but your point is can you not come up with a diagnostic test? As, as-
- PAPeter Attia
Well-
- NCNav Chandel
So, so Herceptin-
- PAPeter Attia
So I'll play it one step forward, right?
- 1:25:25 – 1:29:34
How pollution and viral infections trigger inflammation, and the potential role of metformin as therapy
- NCNav Chandel
effect. So I'm gonna give you the third one. This is the one every day I wrestle with, Peter. Should I do it? Should I... And inflammation.
- PAPeter Attia
Hmm.
- NCNav Chandel
Right? Okay, so I take a statin now even though I don't need to. I take a very low dose statin. And at 50 I decided, go to my doctor, who's a great doctor. Uh, and, um, you know, also with Indian genetics, there can be... But I had pretty good numbers, but I, and listening to you of course. Uh, um, so I have something for that, right? I, I exercise. I have something for my muscle, be social, et cetera. All those sleep, et cetera, right? But for inflammation, and I've been thinking a lot more about inflammation. So the city of Chicago, which had terrible pollution for a long time, really cleaned up its act the last 20 years. Except this past summer, thanks to the Canadian wildfires, it's raging. But, but at one day, I think we were the worst in the world. And I- I- I, and trust me, the last 20 years we've had-- You can look at the data. We- we're not a, we're not a terribly polluted city, at least where I live. Uh, we've done trees on top of trees, on, you know, on homes, et cetera. We've done a lot to make ourselves not, and now we have this. So what is, is, what are you gonna fight against pollution, right? Pollution induced inflammation. So my friend Scott Budinger and, and Gokhan Mutlu, um, at Northwestern, years ago, they were giving Beijing level pollution to mice. And one cytokine goes up robustly in humans and in mice, IL-6. And IL-6 makes you prothrombotic. Uh, therefore you're susceptible to cardiovascular injuries. You know, an MI, for example, right? Okay. Uh, and they started taking alveolar macrophages and giving it low dose pollution in vitro, and they noticed that the pollutants, this, this particulate matter, uh, these small particles were going in the mitochondria and increasing that H2O2 signal. And they could show that H2O2 signal was responsible for the IL-6 production. So is pollution, particulate matter pollution, mitochondria increasing H2O2, not to kill, as a signal for inflammation.
- PAPeter Attia
And by the way, does the pollution have to be PM 2.5? It ha- does it have to be?
- NCNav Chandel
I, I think so. It was that one.
- PAPeter Attia
Yeah. Okay.
- NCNav Chandel
That's what they did. Yeah. Uh, yep. And [laughs] the crazy thing is I was like, "Oh, Scott, you gotta put metformin." And he goes, "What do you mean?" Like, "Metformin inhibits complex one, and it'll prevent the H2O2 from being released." He's like, "Okay." So they did it in vitro and in vivo. It's a public paper in cell metabolism. And beautifully, they could show in vivo giving it, uh, in the drinking water that it lowered the IL-6.
- PAPeter Attia
And is that because the liver is making-- I mean, uh-
- NCNav Chandel
The alveolar macrophages-
- PAPeter Attia
It's the alveolar macrophages?
- NCNav Chandel
It, it got to the alveolar macrophages. They took it up because we could see in, in the alveolar macrophages is-
- PAPeter Attia
How are they getting the metformin?
- NCNav Chandel
They're, they're taking it up.
- PAPeter Attia
Out of the blood?
- NCNav Chandel
Out of the blood.
- PAPeter Attia
So they have o- OCTs.
- NCNav Chandel
They have the transporters, but, but they, they're good at, at, uh, uh, I think at also taking up stuff. Uh, uh, what we wanna do is put NDI1 back in those macrophages to definitively show it did take it up and it inhibit complex one. Because it could have been an effect from somewhere else still, right? It maybe the gut, everything. But, but the key point is we're still working on the mechanism, um, Peter. And we've done, by the way, we've given flu, u, with metformin, uh, and there was always a COVID signal, uh, with metformin decreasing, uh, uh, the inflammation. So, uh, in mouse models of SARS-CoV-2 or influenza, when people give drinking water metformin, it lowers the pathology. But my simple point was, I'm gonna be exposed to pollution. Again, there's no human data with metformin and pollution measuring CRP or something like that, uh, for a couple of months and seeing if it was lower at a population level.
- PAPeter Attia
What do you think IL-6 would be more sensitive than CRP?
- NCNav Chandel
I think CRPs, uh, would be equally sensitive, I think. But again, um, it's, it's, people just haven't designed the trials correctly to
- 1:29:34 – 1:31:51
Clonal hematopoiesis, inflammation, and mitochondrial metabolism: metformin’s role in limiting age-related immune dysregulation
- NCNav Chandel
think about this. So here's a last one about inflammation. Do you know what clonal hematopoiesis is?
- PAPeter Attia
Yes.
- NCNav Chandel
Right? So this is as we age-
- PAPeter Attia
But tell people because-
- NCNav Chandel
Right
- PAPeter Attia
... it's an important part of heart disease that doesn't, we probably don't spend enough time talking about it.
- NCNav Chandel
Yeah. So, so as we age, age, um, uh, our hematopoietic, uh, stem cells, which make all our blood cells, including our T cells and our B cells and our red blood cells and our platelets, as we age, those, uh, uh, can pick up a particular mutation and, and, and actually mutation in the enzymes that run epigenetics largely. And they become rogue clones, and they overtake. Uh, and they somehow contribute to cardiovascular disease, definitely inflammation. And the level of clonal hematopoiesis can range from three to twenty percent, and of these rogue clones taking over as we age. So UK Biobank did this study. They looked at clonal hematopoiesis, and they somehow, and I'm not an epidemiologist, controlled for diabetes and everything. People on metformin had lower incidence of clonal hematopoiesis. Four hundred and fifty thousand UK Biobank. The same people made a mouse model of h- of clonal hematopoiesis, and they gave, uh, metformin. It decreased clonal hematopoiesis.
- PAPeter Attia
How much?
- NCNav Chandel
Uh, very significantly. It was, it was, it was quite remarkable. Here's the best part. Some smart reviewer said, "You should put NDI1 and show me it's complex one." And it was. So in other words, metformin binding to complex one prevented those clones from outgrowing from the mechanism you pointed out because the building blocks weren't there.
- PAPeter Attia
But again, how are we getting so lucky that These cells have OCTs
- NCNav Chandel
I, I was, to be honest with you, the dosing they did was, was fifty micromolar in vitro, uh, uh, to have some of these effects. I was shocked.
- PAPeter Attia
And they were doing this in human cells?
- NCNav Chandel
Yeah. They did it in mouse cells. Yeah. Three papers came out at the same time to the same conclusion. So speaking of reproducibility, uh, three different ways. Uh, two of them were in Nature, the other one was in Nature Communications. All three of them said if you inhibit electron transport chain, you can prevent clonal hematopoiesis, and the best drug that is safe if is metformin. So, so Peter, let's, let's just wrap
- 1:31:51 – 1:38:23
Takeaways on the benefits and risks of using metformin as a geroprotective drug
- NCNav Chandel
up the metformin. There's a couple of lessons in the, in the metformin. And on the mechanism side, right, um, and we're gonna get into your some of your other s- uh, favorite supplements perhaps, we should first think about when you take an oral supplement or an oral drug, where does it go? Does it accumulate everywhere, or does it only go certain places? The second thing we have to know is what is its target? I've argued it's complex one and because I've made a complex one that is refractory to metformin binding but works like complex one. So someone should always show me the target and make that target work perfectly fine but not bind to metformin or whatever other drug or supplement. And the third one is maybe you don't even care about where it goes as, and what it binds to. Does it work in humans, not in mice only, right? And so the data suggest, and, and you, you tell me if you agree with this, as in a normal person, it'll, it'll keep your glucose levels down, hmm, if you take it before a meal, not a bad thing. If you get lucky, if it has that transporter, then it will, um, perhaps lower the clones from, the cancer clones from, from arising and if you're lucky to have that. The third one is clonal hematopoiesis that happens with age, it lowers according to these, uh, studies. And in our study with pollution and, and in some studies that people have done with T cells, it seems to be a, a low, uh, sort of, uh, a low inflam- anti-inflammatory agent. So is, so is that enough for people to take it? So, so what are the risks? The risk is B12 deficiency, but you can fix that. The other one is citrulline. You can easily take supplement for that. Uh, people get nausea, so people sometimes people don't take it, but many people don't. So that's where we're at.
- PAPeter Attia
Do you think it cross-reacts or interferes with other glycemic agents such as GLP-1 agonists or-
- NCNav Chandel
Yeah. I've asked-
- PAPeter Attia
Yeah
- NCNav Chandel
... yeah, what do you think? I've asked people that. They say no.
- PAPeter Attia
I don't, I don't think I have an informed enough opinion.
- NCNav Chandel
I just don't. Yeah, I don't either. Um, um, there are people who do both, as you know. Um, so I, I, I, I, I just don't. So it's the inflammation part, right? 'Cause I'm not gonna take an NSAID, right? I'm not gonna take Aleve every day. I take it sometimes, and that's pretty potent.
- PAPeter Attia
But then the question becomes like why did aspirin fail in the ITP, right? Why, why would COX inhibition, which should be reducing inflammation, had no impact on or-
- NCNav Chandel
Well, it reduces different kinds of inflammation perhaps, right?
- PAPeter Attia
Yeah.
- NCNav Chandel
It, right, this is much more. So we can show metformin inhibits-
- PAPeter Attia
So, so-
- NCNav Chandel
... the IL-one beta, IL-six. You know?
- PAPeter Attia
So what would we need to do in humans, right? I've lost track. W- is TAME happening? What's, what's going on?
- NCNav Chandel
I don't know.
- PAPeter Attia
Okay.
- NCNav Chandel
I don't know. But, but again, and, uh, the, the cancer trials, the TAME trials, every trial, uh, in metformin, um, because it's cheap, it's been guided, um, you know, smartly by whatever data is in humans. And could we redo these trials based on mechanism? Mechanism being the insights we have now.
- PAPeter Attia
Yeah.
- NCNav Chandel
Put glucose monitors just to see, uh, you know, over a year how well did the metformin that people took just to know whether it did anything. Maybe it doesn't. Maybe some people, for whatever reason, it doesn't get absorbed. Maybe their transporters are low, uh, right? So have some indication and maybe measure CRP or some other, uh, measure clonal hematopoiesis if there's ways to do that, right? There's, there's all of this sort of stuff. As far as the cancer, that's almost impossible. You're just taking it, you know, uh, something that may help protect against, uh, or if you get an early lesion, it might slow it down. And but I like the inflammation and the lowering glucose as the two actionable ones. And is, is there anything else that really can do that?
- PAPeter Attia
Well, I think if you're lowering, uh, CHIP, that's, that's pretty interesting.
- NCNav Chandel
Yeah, yeah. We'll have to see how well that, that, uh, that manages. Right. So-
- PAPeter Attia
And that hasn't been demonstrated in human, uh, cells yet?
- NCNav Chandel
Well, well, it has, uh, and it has been also demonstrated in the UK Biobank as just a correlation.
- PAPeter Attia
Yes, but it hasn't been proactively tested in humans.
- NCNav Chandel
Well, it does-- Uh, no, no, no. You mean as a clinical trial? No, no. Uh, someone needs to do that.
- PAPeter Attia
Yeah.
- NCNav Chandel
And, and then, but it'll take five years, right?
- PAPeter Attia
But that would be a very interesting trial in a high-risk population.
- NCNav Chandel
Yes.
- PAPeter Attia
You take a high-risk cardiovascular disease population that is otherwise well managed, 'cause one of the questions I find interesting-
- 1:38:23 – 1:41:01
Views on tests that claim to measure mitochondrial function
- NCNav Chandel
so well.
- PAPeter Attia
Now, I wanna talk about a whole bunch of supplements-
- NCNav Chandel
Yeah
- PAPeter Attia
... that get talked about a lot. Before I do, though, um, I just wanna go back to something you said at the outset. I asked you, "Hey, how would you measure mitochondrial function?" And you said, "I'd put a needle in somebody and pull out tissue." [laughs]
- NCNav Chandel
Well, yeah.
- PAPeter Attia
And, and, but, but that's important because there are lots of people out there that are hawking tests-
- NCNav Chandel
Right
- PAPeter Attia
... that are claiming they have tests. They have blood tests, they have breath tests, they have all sorts of tests to measure mitochondrial function. As one of the world's experts on this topic, are you aware of any blood test, breath test, a- any sort of, uh, test that a person can do to measure their mitochondrial function? If they see this, what should they be thinking?
- NCNav Chandel
I have not looked at all these tests. I don't follow these tests. I s- I don't care to. Uh, simply because in a perfect world, I can't think of how I would design it for all the reasons we just talked about. That's the real problem. I mean, look, if I had one, then maybe, you know, this struggling scientist professionally and personally would, uh, [laughs] would come up with one, Peter. But, you know, I got nothing other than a cheap drug called metformin and a glucose monitor, you know? So it's, it's difficult for me to imagine how that test looks like and whether it reproducibly measures something that has, uh, value.
- PAPeter Attia
'Cause I'm assuming what these tests are trying to measure are-
- NCNav Chandel
Discontent.
- PAPeter Attia
Well, yeah, I assume... I, again, I'm not, I'm also not an expert in this whatsoever. I assume they're measuring metabolic intermediates, and they're somehow trying to impute based on your arginine, ornithine, citrulline levels, alpha-ketoglutarate levels. Oh, based on that, based on the ratios and levels-
- NCNav Chandel
Yeah
- PAPeter Attia
... of all these things, we can tell you how your mitochondrial function-
- NCNav Chandel
Or, or acylcarnitine.
- PAPeter Attia
Yeah. Why is that kind of bogus in your mind?
- NCNav Chandel
Well, because, A, it's in steady state. It doesn't really tell you flux, which is how fast the system is running or not running. You could see an increase in something. Is that because you're running so fast and you still have a lot, or is it something backed up? That's problem one.
- PAPeter Attia
Yep.
- NCNav Chandel
Right? A, so-
- PAPeter Attia
That's the whole CTAP inhibitor problem back-
- NCNav Chandel
Yeah
- PAPeter Attia
... when we were dealing with that drug.
- NCNav Chandel
Yeah. So it's just, um, yeah. Again, when I myself haven't done a deep dive on something, I generally try not to be overly critical, but I'm just making a philo- I'm making a conceptual point that, you know, if you and I sat together for an afternoon and said, "Here, Nav, tell me all the things I could measure and how would I measure it," could I come up with a test? No.
- PAPeter Attia
All right. Let's talk about some of the most popular supplements that people promote as-
- NCNav Chandel
Can I, can I just finish just with cancer real quick?
- PAPeter Attia
Yeah, yeah.
- NCNav Chandel
We didn't touch cancer
- 1:41:01 – 1:43:36
The Warburg effect and cancer metabolism: why Nav doesn’t think mitochondria in cancer cells are dysfunctional
- NCNav Chandel
because this is another misnomer. People-- So the original hypothesis of cancer, the number one hypothesis of cancer, not number one, but the oldest from the 1920s, was by a m- gentleman, the Warburg effect, that many people have heard. So Otto Warburg got a Nobel Prize for the discovery of cytochrome c oxidase, which is the main oxygen-consuming enzyme of the electron transport chain. Yours truly did his PhD on cytochrome oxidase kinetics. So for me, Otto Warburg, burg, has a place for the discovery of that enzyme electron transport chain. So, so Otto Warburg, mm, in the 1920s, noticed that cancer tissues, those make a lot of lactate on a tabletop compared to normal tissues. There's plenty of oxygen, and so if you have oxygen, you shouldn't be making lactate. So he actually made an intelligent guess, which is that mitochondria of those tissue, of the cancer, is dysfunctional. Their electron transport, he s- called it injury to respiration, his famous line, is a prerequisite for developing cancer. Uh, today we know that many cancers that make a lot of lactate don't do it because electron transport or injury to respiration. In fact, 95, 98% of cancers have a very intact electron transport chain TCA cycle, and the reason is because they use it to make ATP, but also to make those anabolic precursor, the metabolites for growth. There are a few outliers that have a TCA cycle mutation or an electron transport chain mutation, okay? Those tumors that arise is they basically take the m- uh, macromolecules for growth, the metabolites from growth from the, uh, from the blood. They, they, they're good scavengers.
- PAPeter Attia
Yeah. This is, this is an important point to tease out.
- NCNav Chandel
Right?
- PAPeter Attia
So the Warburg effect is in effect. Most cancers adhere to it. It's the causality that's incorrect. It's not that the Warburg effect is the result of deficient electron transport. It's that the Warburg effect is there as a result of a cell that needs to reproduce and grow and grow-
- NCNav Chandel
Yeah
- PAPeter Attia
... and grow and create building blocks.
- NCNav Chandel
Right.
- PAPeter Attia
And really, the first time I read this was in that very famous two thousand and nine-
- NCNav Chandel
Right
- PAPeter Attia
... science paper with Matthew and-
- NCNav Chandel
Matthew. Yeah, yeah, yeah
- PAPeter Attia
... and Lou-
- NCNav Chandel
Craig and Lou
- PAPeter Attia
... and Craig.
- NCNav Chandel
Yeah. Yeah.
- PAPeter Attia
Um, so, so very important distinction. But unfortunately, this is sort of where the, the internet and, and people who maybe don't fully understand this will turn it into, "Cancer is a mitochondrial disease, and it's all about your mitochondria, and if you just take mitochondrial supplements, you'll never get cancer." Like that somehow-- Or, "If you have cancer, just take mitochondrial supplements, you're gonna be fine."
- NCNav Chandel
Yeah, yeah.
- PAPeter Attia
Yeah, yeah. This is complete
- 1:43:36 – 1:52:28
Mitochondrial supplements: urolithin A and berberine
- PAPeter Attia
and utter nonsense.
- NCNav Chandel
Yes.
- PAPeter Attia
Okay.
- NCNav Chandel
Yes. Yes.
- PAPeter Attia
So, uh, let's turn to some famous mitochondrial supplements.
- NCNav Chandel
Right.
- PAPeter Attia
Uh, urolithin.
- NCNav Chandel
Right.
- PAPeter Attia
Okay. What can you tell us about urolithin?
- NCNav Chandel
We're gonna use the metformin principles all over again. Oral.
- PAPeter Attia
Yep.
- NCNav Chandel
First pass, gut. Uh, uh, the gut cells do take it up. Uh, the second pass very quickly, liver. I actually didn't know this until recently, eh, because I went back and read a, a very nice paper. Uh, I think one of your guests previously might have been on, I think it was on the paper on inflammation and urolithin. If you look at the supplementary data, uh, how much is in the plasma of urolithin of those people who took it? Picograms. Undetectable. Because the liver puts glucuronic acid on it. So it's urolithin then conjugated, which then is in the plasma. So you can barely detect urolithin in the plasma. Its conjugate, urolithin plus this sugar moiety, eh, is higher, like five to ten micromolar. That moiety cannot get into a cell. Urolithin can.
- PAPeter Attia
So what breaks the conjugate?
- NCNav Chandel
So there are enzymes, -ymes, that can break that conjugate. Uh, they're usually found around immune cells, sometimes on, in muscle repair tumors, -ers. But this is a bit of a conundrum I don't quite understand, right? And I'm sure you appreciate where I'm going with this, is like, well, hang on, how does this work? Uh, this, this thing rapidly becomes-- So either it's having effects on the gut directly, which it might, it, and we know how important the gut is. Is, the other thing is that when it's made a conjugate, it has to be deconjugated, and that's happening in my reading of the enzymes that do this tend to be more related to immune cells. Okay? So that's, that's part one. And the second thing is like with metformin, what's its target? So with metformin, people debated, is it complex one? Is it not complex one? Is it complex four? Is it something else? The way we went about showing it's complex one is we found a refractory version of metformin that wouldn't bind and to show it was complex one, right? So with urolithin, they say it's mitophagy, that it promotes, you know, bad mitochondria, it gets rid of them. Okay.
- PAPeter Attia
But wait, wait. I, I, I-
- NCNav Chandel
Yeah
- PAPeter Attia
... I've missed three steps.
- NCNav Chandel
Yeah.
- PAPeter Attia
How is it even getting into a cell?
- NCNav Chandel
Well, I don't know that. So the only way it could get into a cell l- is that locally, uh, like immune cells, for example, uh, again, I don't know the literature that well on it.
- PAPeter Attia
Do we know if there's a urolithin transporter that can get unbound-
- NCNav Chandel
In
- PAPeter Attia
... or unconjugated urolithin from-
- NCNav Chandel
I don't think the conjugated one can get in, in. I think the unconjugated for sure gets in because take-
- PAPeter Attia
So can't, I mean, clearly somebody could label urolithin-
- NCNav Chandel
Yes
- PAPeter Attia
... and give it to somebody and then look at where it's taken up.
- NCNav Chandel
Yes. Exactly.
- PAPeter Attia
Has that been, has that experiment been done?
- NCNav Chandel
I have never seen it. So that's what the metformin experiment was, right?
- 1:52:28 – 1:55:05
Mitochondrial supplements: α-ketoglutarate
- PAPeter Attia
Okay. What about alpha-ketoglutarate?
- NCNav Chandel
I like that one a lot, and I study it myself. Uh, actually, I study a, a different version. Um, uh, something in the family of alpha-ketoglutarate. The reason I like it is because alpha-ketoglutarate, we do have targets, probably too many, 75. So it's, if alpha-ketoglutarate is there, it's gonna run your demethylase enzymes working well, and it'll cut- p- potentially keep DNA methylation levels down. You know, your so-called voodoo epigenetic clocks, so-
- PAPeter Attia
And, and sorry, is it doing that, is it, is it, um, is it keeping methylation down, or is it reducing methyl groups?
- NCNav Chandel
It, no, no, no, no.
- PAPeter Attia
Like, is it competing for-
- NCNav Chandel
No, no, no. So, so, so the methyl groups put it on-
- PAPeter Attia
Yep
- NCNav Chandel
... the DNA. The enzymes that get rid of it, it m- keeps those enzymes from working well.
- PAPeter Attia
Got it. Okay.
- NCNav Chandel
Right? Here's the only issue. How much do you need for alpha-ketoglutarate in a cell to run those enzymes maximally? You know? Hundred micromolar, right? You have a lot of alpha-ketoglutarate. It's remarkable.
- PAPeter Attia
So is it, is it ever rate limiting?
- NCNav Chandel
Is it ever rate limiting? [laughs] I don't know that. Uh, as we age, it does go down, but does it go down enough?
- PAPeter Attia
So what's the experiment?
- NCNav Chandel
Um, so-
- PAPeter Attia
What's been done?
- NCNav Chandel
Well, people are now giving alpha-ketoglutarate. There's a famous study, I think Brian Kennedy's group did that with, the females, uh, uh, had a better, uh, outcome than males did, the, the mice did, and they're doing human trials. And I mean, and hopefully they'll do them enough that we'll get parameters. But I could imagine, like, alpha-ketoglutarate, again, working for inflammation under certain conditions. Or, or one of my favorite studies, uh, and I wrote a, a perspective on it, it's not my study, it came out of other groups, uh, where they gave alpha-ketoglutarate genetically, they, they manipulated or a supplement, and it helped against colitis. It happened against 5-FU, the chemotherapeutic drug. So in other words, it maintained gut health. It promoted stem cells to become more secretory compared to absorptive, which help maintain in gut health. Could you imagine giving alpha-ketoglutarate in those settings, right? So instead of thinking of a geroprotective-
- PAPeter Attia
Yeah, they're very niche
- NCNav Chandel
... narrow it down, right?
- PAPeter Attia
Yeah.
- NCNav Chandel
These are g- to me, they're gonna be niche, and I think people who are doing them maybe should think about them. You know, it's like, uh, you love this study. I know I do.
- PAPeter Attia
But, but, but to, to-
- NCNav Chandel
The rapamycin vaccination one.
- PAPeter Attia
Yeah. Yeah, exactly.
- NCNav Chandel
The rapamycin. Yeah, I love that study.
- PAPeter Attia
But to do this, you, you really need to go down an IND pathway as opposed to a supplement pathway.
- NCNav Chandel
Yeah.
- PAPeter Attia
You're, you have to turn, you have to turn this into a drug.
- NCNav Chandel
Yeah.
- PAPeter Attia
Right? You, you have to have an indication.
- NCNav Chandel
Yeah.
- 1:55:05 – 1:58:10
Mitochondrial supplements: citrulline, carnitine, CoQ10, NR, and NMN
- NCNav Chandel
Yeah.
- PAPeter Attia
Um, okay, citrulline
- NCNav Chandel
Uh, well, we just said that it, it, uh, can put-
- PAPeter Attia
Potentially with metformin
- NCNav Chandel
... potentially with metformin, yeah.
- PAPeter Attia
Okay. Carnitine
- NCNav Chandel
[laughs] Well, carnitine helps get fatty acids into the mitochondria. That's what carnitine does. The question is-
- PAPeter Attia
Is it meaningful? Is it rate limiting?
- NCNav Chandel
Is it rate limiting? I go back to the rate limiting. Do you, you and I, I, I assume you're still a meat eater. Uh, I am. Um, you know, and even people who don't eat meat, they probably get sufficient amount of carnitine and to have your fatty acids working. So-
- PAPeter Attia
All right, the big one, CoQ10
- NCNav Chandel
[laughs] Um, I think s- statins, it makes sense sometimes, uh, because it can hit the CoQ pathway upstream. So you can imagine certain, um, statins, maybe they get in the muscle high enough are lowering CoQ levels. Does it get to the point where CoQ, again, becomes rate limiting? And so a- anecdotally, I mean, you know this better than I do, Peter, people say that the CoQ helps them. Um, uh, and I can-
- PAPeter Attia
I feel like the trials have not been successful
- NCNav Chandel
Not shown that, yeah
- PAPeter Attia
Yeah
- NCNav Chandel
Uh, again, there's a bioavailability problem. Um, um, but for what else would you use it for? For normal health? No. You have enough CoQ.
- PAPeter Attia
Okay. Now, we've already talked a little bit about NAD, so anything you want to say about the NAD precursors NR and NMN?
- NCNav Chandel
To the listeners, there was a nice article written in The New York Times recently about NAD, does it work? They got a lot of experts. I like that article a lot. The experts were very good about, uh, uh, you know, making their disclosures. Uh, they have a company, they don't have a company, so that was important. Uh, if you read the article, even those experts say, you know, does NAD, again, decline in normal aging to levels that become rate limiting? And the answer seems largely no. Uh, again, could the NAD precursors be used in a special setting? So there's a view-
- PAPeter Attia
Certain disease setting
- NCNav Chandel
... certain disease. So, or, or f- so there's a nice paper that came that liver regeneration can be boosted yesterday by giving NAD supplements from a reputable group
- PAPeter Attia
What, what, wh- sorry, what can be boosted?
- NCNav Chandel
Liver regeneration
- PAPeter Attia
Oh, liver regeneration
- NCNav Chandel
Yeah. So you could... I, and I can, and the mechanisms and what they talked about kinda made sense to me, and it's a nicely done study from a very reputable person at University of Pennsylvania, Joe Bauer. So I, I like that study. So I can totally imagine-
- PAPeter Attia
But liver regeneration after liver surgery or after transplant surgery
- NCNav Chandel
Yeah. Some, exactly, yeah
- PAPeter Attia
I mean, it's pretty, pretty extreme cases
- NCNav Chandel
Pretty extreme, right? It, same with could it work for anti-tumor immunity? Could it work under special conditions, et cetera, et cetera? Absolutely, I'm open to that, but, but not for geroprotective. Uh, I just don't see how, and it's based on mitochondrial dysfunction causes the mitochondria not to regenerate NAD, 'cause that's what mitochondria do. Let's give NAD supplements
- PAPeter Attia
Yeah, which again, we should point out was unsuccessful in the ITP. Um, okay,
- 1:58:10 – 2:02:31
Interventions touted to boost mitochondrial health: SS-31 and methylene blue
- PAPeter Attia
SS-31. Now this is actually pharmaceutical grade. This is treating, what's it called? Bart's dy-
- NCNav Chandel
Bart syndrome
- PAPeter Attia
Bart syndrome
- NCNav Chandel
So this is because there is a l- a mutation in a gene, and that makes cardiolipin. Cardiolipin is found in mitochondria. Again, it is necessary for cytochrome c oxidase that Otto Warburg did his research on, uh, did his, uh, PhD on. And, uh, cardiolipin levels dictate the efficiency of that enzyme to work. Like, it uses the oxygen, makes ATP, et cetera. Um, these people have low amounts, and the FDA approved this SS-31 as a way to stabilize the little cardiolipin there to boost the efficiency of that enzyme. Some people argue that this SS-35, which is-
- PAPeter Attia
31
- NCNav Chandel
... SS-31 interacts with a lot of proteins and overall, like, is like a glue to the electron transport chain. Here's another one, by the way. I would say we don't know the mechanism at all
- PAPeter Attia
The drug is delivered intramuscularly? How is it delivered?
- NCNav Chandel
I don't actually know. I don't know how it's delivered
- PAPeter Attia
Okay
- NCNav Chandel
And, uh, but, but we don't know. There is not an exact target of that drug or even a good putative hypothesis other than it's cardiolipin. Okay?
- PAPeter Attia
Yeah. So that, it's a drug that's shown a very, very weak effect in a very, very extreme and rare genetic disease, but it is being touted as a mitochondrial-boosting drug that should be taken by everybody. What is the case for that?
- NCNav Chandel
Uh, again, are mitochondria being... Is your mitochondria rate limiting right now? No
- PAPeter Attia
Well, or, or is, is cardiolipin rate limiting?
- NCNav Chandel
Cardiolipin rate limiting, fine. Yeah, because the trial was done in, in cardiolipin depleted conditions, and, uh, I would argue no. So, so I don't... Again, the drug could be repurposed in certain mitochondrial mutation patients, which might have some problems, and I'm sure they're gonna test it now in those settings, and I hope it works, because there, there is a deficiency. But for you and I and for most people, I just don't see that
- PAPeter Attia
And how about methylene blue? Which, again, has a very clear clinical indication
- NCNav Chandel
Yeah
- PAPeter Attia
Uh, but beyond, beyond the clinical indication
- NCNav Chandel
Yeah, yeah
- PAPeter Attia
Uh, where do you see it? Is it something we should be just generally taking for mitochondrial health?
- NCNav Chandel
Well, um, I'm glad you asked methylene blue. We're gonna go back to my old friend cytochrome oxidase again. Isn't it amazing how all these supplements somehow interact with the things we've been thinking about for [laughs] for years? So what it does is, is complex I has NADH. It goes to III and IV. I and III can generate a superoxide and H2O2. What it c- IV cannot. It takes electrons from complex I, methylene blue from NADH, and it passes it on to complex IV, which gives it to oxygen. You bypass I and III-
- PAPeter Attia
Sorry, gets II
- NCNav Chandel
Goes, goes from I? So usually you go from I and III-
- PAPeter Attia
I and II. Oh, I thought it was I, IV. Okay
- NCNav Chandel
So one and, so I and II both go into III-
- PAPeter Attia
Yeah, yeah, okay. That's right
- NCNav Chandel
... of electron transport chain. III goes to IV I'm saying it takes electrons from one and gives it to four. That's what methylene blue does. Now, one and three cannot generate as many electrons for H2O2. Uh, so you can imagine diseases where H2O2 signaling is a problem. Maybe methylene blue is a way to, to, uh, to decrease those electrons from generating. But again, you know, is that, that's a hypothesis that I have of, uh, that that's how if it could work, it would work. But how much does it get in? And as you know, it can hi- inhibit monoamine oxidases, which detoxify dopamine and serotonin, and people on serotonin, um, uh, receptor uptakes, right? It, if you take too much of methylene blue, you could get serotonin toxicity. The levels that people take are much lower. Uh, but, but you know, the biology hasn't been really worked out of methylene blue.
- PAPeter Attia
Yeah, my, my-
- NCNav Chandel
And the trials are-
- PAPeter Attia
Yeah, and also I think the, the, the therapeutic window of that drug is pretty narrow.
- NCNav Chandel
Very narrow for that reason.
- 2:02:31 – 2:07:21
Hyperbaric oxygen and low-oxygen therapy: any real benefits for health and longevity?
- PAPeter Attia
what about hyperbaric oxygen?
- NCNav Chandel
[laughs]
- PAPeter Attia
I get asked about this all the time. It's amazing how many times a week I get asked by somebody if they should buy a hyperbaric oxygen chamber.
- NCNav Chandel
No. Please don't. So people are both into high oxygen and low oxygen therapy. A- and, uh, this one is for sure bad. Uh, the ju-
- PAPeter Attia
Outside of wound healing. I mean, it is.
- NCNav Chandel
Outside of wound healing.
- PAPeter Attia
Yeah.
- NCNav Chandel
Yes, yes. So we've-- I've worked a lot on both of them. In fact, I got my whole career started on working on low oxygen, and, and then we moved to high oxygen. What I can tell you in high oxygen, now, to be fair, people do this for a short amount of time, 60 minutes. If you take people, uh, in the ICU and you keep them on high oxygen, they wanna-- they-- I, I work in an ICU department. I'm not a physician, but I talk to them. They are dying to get those people off high oxygen. And, and because the longer you keep somebody on high oxygen, and we've done mice experiments on high oxygen, it causes senescence of your lung epithelial cells. It causes cell death. Uh, it's, there's, there's been absolutely no benefit to the lung being exposed to that level of oxygen. Now, is 60 minutes gonna cause all sorts of-- Probably not. But if you're doing it all the time, um, I don't think it's gonna cause cell death, but it might cause cell senescence, and that's my one worry about it. I just, I've worked with high oxygen mainly in cell culture, mainly in animals. Those, it's nothing good has ever come out.
- PAPeter Attia
But you, you realize why all of this attention exists, right? Like, why-- You might-- Like, why do, why are people so obsessed with hyperbaric oxygen? I think it comes back to that very, um, [lips smack] uh, I'm gonna try hard not to editorialize my thoughts. It, it, it comes back to that Israeli study from a few years ago that looked at telomere length-
- NCNav Chandel
Oh, yeah, yeah, yeah, yeah, yeah, yeah, yeah
- PAPeter Attia
... in, in this. And so, so unfortunately, if, if you were to incorrectly believe that telomere length has anything to do with longevity, you would look at that study and say, "But look, these people, they sat in hyperbaric oxygen chambers. Their telomeres got longer. Clearly, that has an anti-aging benefit." So, um-
- NCNav Chandel
Many holes there.
- PAPeter Attia
Uh, I mean, the, these are ho-
- NCNav Chandel
Starting with the telomere length hypothesis.
- PAPeter Attia
Yeah, yeah, yeah, exactly. These, these are the kind of holes you can drive 18-wheel trucks through.
- NCNav Chandel
Yeah.
- PAPeter Attia
Uh, so aside from that study, is there any-
- NCNav Chandel
No
- PAPeter Attia
... is there anything else that is generating this belief?
- NCNav Chandel
Well, I think the other one is more oxygen, better for the mitochondria. Maybe.
- PAPeter Attia
Okay.
- NCNav Chandel
Right?
- PAPeter Attia
Well, let's talk about the other end of that spectrum.
- NCNav Chandel
Low oxygen.
- PAPeter Attia
Low oxygen therapy seems pretty good for athletes.
- NCNav Chandel
Yeah. So, so what's nice about low oxygen is that low oxygen, and so unl- so high oxygen, there's no receptors for high oxygen. Okay, high oxygen largely, if it's very high, we've shown this, causes oxidative stress at damaging levels. So we can engineer a mouse and overexpress one of these antioxidant proteins, and the mouse dies, and now the mouse lives longer. We've actually, the apoptosis cell death pathway, if we disengage that, it, people, the mice can survive hyperoxia. So hyperoxia, and we can show it causes senescence, cell death. So, so we have, uh, pathways, is, but there's not a direct way hyperoxia is causing that. I think it's just causing so much oxygen that you just make a lot of free radicals or destabilizing the respiratory chain. The low oxygen has a very nice s- system, which is called, well, the HIF prolyl hydroxylase VHL. Uh, Greg Semenza, Peter Ratcliffe, Bill Kaelin got the 2019 Nobel Prize on this. And so when we're hypoxic, this pathway gets activated. One of the consequences is EPO, erythropoietin, which increases your hematocrit. Uh, the other thing is, uh, the low oxygen increases your, [heavy breathing] your ventilation, right? Uh, the pulmonary system vasoconstricts. Those are independent of HIF. Years ago, we showed likely the sensor for those is mitochondrial. There's probably many other things hypoxia does.
- PAPeter Attia
Uh, outside of an athlete who wants to increase red blood cell production-
- NCNav Chandel
Yeah, yeah
- PAPeter Attia
... is there any reason for a normal person-
- NCNav Chandel
No
- 2:07:21 – 2:11:50
Red light therapy: exploring its effects on mitochondria via cytochrome c oxidase and whether purported benefits have a real basis
- NCNav Chandel
I don't, I don't think so.
- PAPeter Attia
All right, let's bring it back to cytochrome again, red light therapy. [laughs]
- NCNav Chandel
[laughs] Apparently, it hits cytochrome c oxidase.
- PAPeter Attia
Yeah, exactly.
- NCNav Chandel
My, my enzyme. Um, how-- It, you know, it's weird. So people say that we always have a little bit of nitric oxide around in our bodies, and NO can bind to cytochrome oxidase, and red light therapy would pop it off and make it more efficient. I actually don't know how red light Um, therapy is having its effects in vivo. By the way, the way we showed metformin and complex I inhibition with NDI 1, there is an ancient enzyme, not from yeast, but from C. scord. If you inhibit complex I, you can override it with this alternative oxidase. So I have a way to test that. Uh, if, again, will I test red light theory? Well, unless it's having these m- as clinical trials that show something amazing, we have a good way to test that theory.
- PAPeter Attia
So, so we-- I mean, the one thing where clinical trials have definitely shown efficacy for red light is in skin rejuvenation.
- NCNav Chandel
Yeah.
- PAPeter Attia
Right? So do you-- I mean, and I, I, I, I feel like I used to know how this worked. Uh, is that working through-
- NCNav Chandel
Photodynamic theory
- PAPeter Attia
... collagen synthesis?
- NCNav Chandel
Yeah, but, but again, um, years ago, we showed that a little bit of H2O2 in skin cells, in epithelial cells, those promoted their differentiation. And people argue that red light therapy could increase a little bit of H2O2, and I wonder if it's the mechanism we found years ago. So l- so I wouldn't mind studying it if it's really true. So, but-
- PAPeter Attia
There, there's another interesting benefit that, that you see in some of the trials on, in red light therapy, which is on a s- if you get a significant enough portion of your body covered in red light, you see glucose uptake enhanced. Um-
- NCNav Chandel
Huh
- PAPeter Attia
... it's, it's, it's actually pretty interesting. So there was-
- NCNav Chandel
I didn't know that
- PAPeter Attia
... there was one study that looked at oral glucose tolerance tests, and the AUC, the area under the curve of glucose-
- NCNav Chandel
Oh
- PAPeter Attia
... went down when a person had X amount of time of their back being hit with red light. Now, I remember when-
- NCNav Chandel
Huh
- PAPeter Attia
... I read this, I was like, "Wow, that's, that's a lot." It was a, actually a pretty significant reduction in AUC. Um, but then I did sort of back of the envelope math to see how it compared to exercising. And of course, it wasn't as much glucose reduction as you would get from an equal amount of time of modest exercise. But it was a lot relative to just laying there, given the fact that you compare it to the placebo. So again, I don't recall sort of thinking through the mechanism. I don't re-
- NCNav Chandel
But smell-- Wait, but doesn't that smell like maybe in the back of the skin, maybe it inhibited cytochrome oxidase, which would then force glucose uptake, eh, kinda like the gut metformin.
- PAPeter Attia
Yeah, yeah, yeah. I guess that's it.
- NCNav Chandel
Maybe, maybe-
- PAPeter Attia
It's, it's just-
- NCNav Chandel
... maybe as simple as that.
- PAPeter Attia
And it's in-- I remember wondering-
- NCNav Chandel
Right?
- PAPeter Attia
... maybe they did. I don't know if they measured lactate, but you would expect to see lactate go up-
- NCNav Chandel
Yeah
- PAPeter Attia
... if it was forcing more glycolysis, right?
- 2:11:50 – 2:18:16
The case for funding basic research to understand metabolism
- NCNav Chandel
Right.
- PAPeter Attia
Um, anyway, Nav, this has been absolutely fascinating. Um-
- NCNav Chandel
Can I-
- PAPeter Attia
I-
- NCNav Chandel
Can I make one other point?
- PAPeter Attia
Oh, please.
- NCNav Chandel
Just, just, and, and this is a bit self-serving. I, I have no conflict of interest, as I said. As we have gone through all these journey about what mitochondria do, and especially all the supplements and all the big drugs, is they all end up doing something, GLP-1, we didn't talk about SGL2, metformin, all the supplements. They have something to do with metabolism, something to do with mitochondria. Thirty years ago, we put money, 40 years ago, we started to put money in the Human Genome Project, which I think has been a complete spectacular, a success. We know the genome, all the sequencing technologies that came out. We've really gotten the granularity of human genetics more and more. UK Biobank, all of this has come of age, right? We have never had a moonshot for metabolism, whether it's the government, whether it's a foundation, whether it's philanthropy. To be clear, places like Michael J. Fox Foundation for Parkinson's, and s- you know, and I have a grant from them, and we think Parkinson's is a complex one disease, and we're trying gene therapy with this NDI1 and to-
- PAPeter Attia
Mm.
- NCNav Chandel
And they've given us some money, so I'm very thankful to them, and we get some money from the government over the years to do all our work. But it's not at scale. Nothing like the Human Genome Project, right? So my thing is, I know academia, there's some issues, as, but right now, we should be doubling our efforts, efforts in science, especially in metabolism, which has been underfunded for 40 years. I mean, you make a great point.
- PAPeter Attia
Why do you think that is, Nav?
- NCNav Chandel
Well, because-
- PAPeter Attia
Is it simply that it got dwarfed by the genomic revolution?
- NCNav Chandel
It got dwarfed by the genomic revolution.
- PAPeter Attia
Yeah.
- NCNav Chandel
And, and, and you remember when you were a student, they said, "Now we, we know our genome-
- PAPeter Attia
We know everything
- NCNav Chandel
... we're gonna know everything about the human disease. 30 years from now, this will not exist. Gene therapy, well, it works great for monogenic diseases and some other diseases, but everything else is idiopathic, unknown etiology. All the tox-
- PAPeter Attia
Polygenic, yep.
- NCNav Chandel
Yeah, but and also the toxins that we're exposed to more and more, like the Parkinson's one, they all hit mitochondria, you know? So but there hasn't been a large scale, and, and, and people like me were early adopters to metabolism after the golden generation of metabolism people all have passed away, the Krebs of the world. And so in my world, there hasn't been that many. Now in, in the next generation, there's a lot more, but I'm afraid they will probably walk away because there won't be enough money for metabolism, uh, 'cause it's dwarfed by the genomic revolution. So I, I really would like people to make a push for the moonshot of metabolism [laughs] .
- PAPeter Attia
But, but, but Nav-
- NCNav Chandel
Um, right
- PAPeter Attia
... do you think it needs to be philanthropy or government? Do you not think this could be biotech driven?
- NCNav Chandel
It co- all, I would, the best case scenario would be all three. That's what the genomics people did, right? There's biotech and genomics for sequencing machines that people buy, right? There's biotech for, for the drugs, but the, the, the basic science comes from, um, uh, the government, and then you have the philanthropy filling in all the holes. Holes. I'm just saying, yes, there is parts of it, but it isn't to scale, right? And I know people are do- you know, have, are down on academia. I would argue we should double, triple our money for biomedical research. So the last 10 years that you talk about, which I completely agree, is what we wanna save. Even if we don't have a healthy population the last 10 years, we're gonna bankrupt the nation, um, because of healthcare costs, you know it and I know it, as people live. At the same time, and I'm on record of saying this, and probably you'll get some flack for this, you have the right, Peter, you do, and the taxpayers, and say, "You know what? Are you being as efficient, or are you being as innovative as you should be for the 21st century in academics' current model?" And I don't think we are. I think it's time that academia change how its business model runs. And but at the same time, give us three times as much money i- in return, uh, [laughs] okay? Hey, so I'm not saying just give us money and we'll keep on doing what we did. We need to change. We need a new model, a new system. I'm very open about it. I will encourage, I know you do notes. Um, I hope you put this. There was a, uh, the grand people in science 10 years ago, people who ran Princeton, NIH director, Nobel Prize. There's four of them who wrote something called Rescuing the Biomedical Research Enterprise. Rescuing. They wrote, like, a white paper in, in the proceedings of the National Academy of Sciences, 'cause they're N- National Academy members, and they outlined what they thought were the problems and solutions. I am not saying we all have to agree on their solutions or even the problems, but it's a pretty good start, and that was 12 years ago.
- PAPeter Attia
And what came of it?
- NCNav Chandel
Nothing. Zero. We did the opposite, in my opinion.
- PAPeter Attia
What were some of the things that they pointed out?
- NCNav Chandel
You know, some of the things about-
- PAPeter Attia
Like risk-taking?
- NCNav Chandel
Risk-taking, some, uh, maybe s- um, different style labs, having, um, um, uh, how, uh, the costs, uh, that the, that the universities impinge on the government. So in other words, getting, um, having more skin in the game. Um, so it's just not a revolving business model. They had a lot of good ideas in there, and, you know, I'm not the right person who's thought about all of this stuff. Uh, what I will say, the biggest challenge, uh, is that, uh, like a lot of things in the US, it's become kind of an imperial power at the top, uh, uh, as opposed to decentralized labs and decentralized, uh, uh, divisions of biochemistry or, or medicine, you know? Where there's, like, you know, if you're Google, you have 10 separate divisions that answers to the top, but they're all kind of independent and decentralized. We're way too centralized now, at every level.
- PAPeter Attia
And you're saying that not just at the NIH level, but at the university level?
Episode duration: 2:18:17
In the uListen app, the transcript lights up word by word as you listen. Get uListen
Transcript of episode nYrLMyUP4S0